Control of mammary tumor differentiation by SKI-606 (bosutinib)

Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia

(2009) Xin Li et al.   AMERICAN JOURNAL OF PATHOLOGY

Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells

(2009) Elena Ezhkova et al.   CELL

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Targeting Src in breast cancer

(2008) R. S. Finn   ANNALS OF ONCOLOGY

Lactation failure in Src knockout mice is due to impaired secretory activation

(2008) Harriet Watkin et al.   BMC DEVELOPMENTAL BIOLOGY

GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer Model

(2008) Hosein Kouros-Mehr et al.   CANCER CELL

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

(2008) A. Vultur et al.   MOLECULAR CANCER THERAPEUTICS

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

(2008) Q Cao et al.   ONCOGENE

Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer

(2008) S. Varambally et al.   SCIENCE